JPWO2020024017A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020024017A5 JPWO2020024017A5 JP2021505981A JP2021505981A JPWO2020024017A5 JP WO2020024017 A5 JPWO2020024017 A5 JP WO2020024017A5 JP 2021505981 A JP2021505981 A JP 2021505981A JP 2021505981 A JP2021505981 A JP 2021505981A JP WO2020024017 A5 JPWO2020024017 A5 JP WO2020024017A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- group
- cycloalkyl
- fibrosis
- halogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 95
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims description 39
- 229910052736 halogen Inorganic materials 0.000 claims description 36
- 150000002367 halogens Chemical class 0.000 claims description 31
- 125000001424 substituent group Chemical group 0.000 claims description 23
- 125000003118 aryl group Chemical group 0.000 claims description 19
- 150000001875 compounds Chemical class 0.000 claims description 19
- 125000001072 heteroaryl group Chemical group 0.000 claims description 19
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 15
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 15
- 229910052739 hydrogen Inorganic materials 0.000 claims description 15
- 239000001257 hydrogen Substances 0.000 claims description 15
- 229910052799 carbon Inorganic materials 0.000 claims description 10
- 125000005842 heteroatom Chemical group 0.000 claims description 10
- 150000002431 hydrogen Chemical class 0.000 claims description 10
- 150000003839 salts Chemical class 0.000 claims description 10
- 239000012453 solvate Substances 0.000 claims description 10
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
- DBTDEFJAFBUGPP-UHFFFAOYSA-N Methanethial Chemical compound S=C DBTDEFJAFBUGPP-UHFFFAOYSA-N 0.000 claims description 5
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 claims description 5
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 5
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 5
- 235000019256 formaldehyde Nutrition 0.000 claims description 5
- 125000005843 halogen group Chemical group 0.000 claims description 5
- 229910052757 nitrogen Inorganic materials 0.000 claims description 5
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 5
- 229910052760 oxygen Inorganic materials 0.000 claims description 5
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 3
- 229910052805 deuterium Inorganic materials 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 206010016654 Fibrosis Diseases 0.000 claims 6
- 230000004761 fibrosis Effects 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 206010028537 myelofibrosis Diseases 0.000 claims 3
- 101001043321 Homo sapiens Lysyl oxidase homolog 1 Proteins 0.000 claims 2
- 101001043352 Homo sapiens Lysyl oxidase homolog 2 Proteins 0.000 claims 2
- 101001043354 Homo sapiens Lysyl oxidase homolog 3 Proteins 0.000 claims 2
- 101001043351 Homo sapiens Lysyl oxidase homolog 4 Proteins 0.000 claims 2
- 208000002260 Keloid Diseases 0.000 claims 2
- 101710159002 L-lactate oxidase Proteins 0.000 claims 2
- 102100021958 Lysyl oxidase homolog 1 Human genes 0.000 claims 2
- 102100021948 Lysyl oxidase homolog 2 Human genes 0.000 claims 2
- 102100021949 Lysyl oxidase homolog 3 Human genes 0.000 claims 2
- 102100021968 Lysyl oxidase homolog 4 Human genes 0.000 claims 2
- 102100026858 Protein-lysine 6-oxidase Human genes 0.000 claims 2
- 208000032056 Radiation Fibrosis Syndrome Diseases 0.000 claims 2
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 2
- 206010042953 Systemic sclerosis Diseases 0.000 claims 2
- 230000002159 abnormal effect Effects 0.000 claims 2
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 2
- 230000009787 cardiac fibrosis Effects 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 210000001117 keloid Anatomy 0.000 claims 2
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 2
- 201000002793 renal fibrosis Diseases 0.000 claims 2
- 230000037390 scarring Effects 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 206010061424 Anal cancer Diseases 0.000 claims 1
- 201000003076 Angiosarcoma Diseases 0.000 claims 1
- 208000007860 Anus Neoplasms Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 208000032544 Cicatrix Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 208000001708 Dupuytren contracture Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 206010060980 Granular cell tumour Diseases 0.000 claims 1
- 208000010496 Heart Arrest Diseases 0.000 claims 1
- 208000001258 Hemangiosarcoma Diseases 0.000 claims 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 1
- 208000024934 IgG4-related mediastinitis Diseases 0.000 claims 1
- 208000014919 IgG4-related retroperitoneal fibrosis Diseases 0.000 claims 1
- 201000003803 Inflammatory myofibroblastic tumor Diseases 0.000 claims 1
- 206010067917 Inflammatory myofibroblastic tumour Diseases 0.000 claims 1
- 206010072877 Intestinal fibrosis Diseases 0.000 claims 1
- 206010023330 Keloid scar Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 208000018142 Leiomyosarcoma Diseases 0.000 claims 1
- 206010024612 Lipoma Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000002805 Mediastinal fibrosis Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000007727 Muscle Tissue Neoplasms Diseases 0.000 claims 1
- 208000003510 Nephrogenic Fibrosing Dermopathy Diseases 0.000 claims 1
- 206010067467 Nephrogenic systemic fibrosis Diseases 0.000 claims 1
- 201000004404 Neurofibroma Diseases 0.000 claims 1
- 108090000854 Oxidoreductases Proteins 0.000 claims 1
- 102000004316 Oxidoreductases Human genes 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000004362 Penile Induration Diseases 0.000 claims 1
- 206010034464 Periarthritis Diseases 0.000 claims 1
- 208000020758 Peyronie disease Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010036805 Progressive massive fibrosis Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 206010038979 Retroperitoneal fibrosis Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 208000003252 Signet Ring Cell Carcinoma Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 208000009887 angiolipoma Diseases 0.000 claims 1
- 230000002300 anti-fibrosis Effects 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 239000002220 antihypertensive agent Substances 0.000 claims 1
- 229940030600 antihypertensive agent Drugs 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 201000011165 anus cancer Diseases 0.000 claims 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 230000036952 cancer formation Effects 0.000 claims 1
- 208000002458 carcinoid tumor Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 230000008021 deposition Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 206010016629 fibroma Diseases 0.000 claims 1
- 206010049444 fibromatosis Diseases 0.000 claims 1
- 239000002657 fibrous material Substances 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 201000006604 granular cell tumor Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 150000004677 hydrates Chemical class 0.000 claims 1
- 206010020718 hyperplasia Diseases 0.000 claims 1
- 230000001969 hypertrophic effect Effects 0.000 claims 1
- 229940125721 immunosuppressive agent Drugs 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 125000001041 indolyl group Chemical group 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000010260 leiomyoma Diseases 0.000 claims 1
- 206010024627 liposarcoma Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000008806 mesenchymal cell neoplasm Diseases 0.000 claims 1
- 230000002503 metabolic effect Effects 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 210000000214 mouth Anatomy 0.000 claims 1
- 208000024305 myofibroblastoma Diseases 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 208000007538 neurilemmoma Diseases 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 230000007170 pathology Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 230000002980 postoperative effect Effects 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims 1
- 231100000241 scar Toxicity 0.000 claims 1
- 230000037387 scars Effects 0.000 claims 1
- 206010039667 schwannoma Diseases 0.000 claims 1
- 201000008123 signet ring cell adenocarcinoma Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 210000004291 uterus Anatomy 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 230000029663 wound healing Effects 0.000 claims 1
- 230000037314 wound repair Effects 0.000 claims 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- PKYCWFICOKSIHZ-UHFFFAOYSA-N 1-(3,7-dihydroxyphenoxazin-10-yl)ethanone Chemical compound OC1=CC=C2N(C(=O)C)C3=CC=C(O)C=C3OC2=C1 PKYCWFICOKSIHZ-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 102100027159 Membrane primary amine oxidase Human genes 0.000 description 1
- 101710132836 Membrane primary amine oxidase Proteins 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- HSSLDCABUXLXKM-UHFFFAOYSA-N resorufin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3N=C21 HSSLDCABUXLXKM-UHFFFAOYSA-N 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2018902829 | 2018-08-03 | ||
| AU2018902829A AU2018902829A0 (en) | 2018-08-03 | Haloallylamine sulfone derivative inhibitors of lysyl oxidases and uses thereof | |
| PCT/AU2019/050811 WO2020024017A1 (en) | 2018-08-03 | 2019-08-02 | Haloallylamine sulfone derivative inhibitors of lysyl oxidases and uses thereof |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021535087A JP2021535087A (ja) | 2021-12-16 |
| JPWO2020024017A5 true JPWO2020024017A5 (https=) | 2022-08-04 |
| JP2021535087A5 JP2021535087A5 (https=) | 2022-08-04 |
| JP7414803B2 JP7414803B2 (ja) | 2024-01-16 |
Family
ID=69230421
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021505981A Active JP7414803B2 (ja) | 2018-08-03 | 2019-08-02 | リシルオキシダーゼのハロアリルアミンスルホン誘導体阻害剤およびそれらの使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US12178791B2 (https=) |
| EP (1) | EP3829520B1 (https=) |
| JP (1) | JP7414803B2 (https=) |
| KR (1) | KR102780601B1 (https=) |
| CN (1) | CN112533897B (https=) |
| AR (1) | AR115906A1 (https=) |
| AU (1) | AU2019315330B2 (https=) |
| CA (1) | CA3105599A1 (https=) |
| ES (1) | ES3010655T3 (https=) |
| MX (1) | MX2021001347A (https=) |
| TW (1) | TW202019877A (https=) |
| WO (1) | WO2020024017A1 (https=) |
| ZA (1) | ZA202100148B (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020317374A1 (en) * | 2019-07-25 | 2022-02-03 | Pharmaxis Ltd. | Difluorohaloallylamine sulfone derivative inhibitors of lysyl oxidases, methods of preparation, and uses thereof |
| US12578335B2 (en) * | 2020-02-05 | 2026-03-17 | Syntara Limited | Bioprobes for lysyl oxidases and uses thereof |
| EP4173639A4 (en) * | 2020-06-26 | 2024-03-13 | RaQualia Pharma Inc. | METHOD FOR SELECTING A CANCER PATIENT FOR WHICH COMBINATION THERAPY OF A RETINOID AND A CANCER TREATMENT AGENT WILL BE EFFECTIVE, AND COMBINATION DRUG OF A RETINOID AND A CANCER TREATMENT AGENT |
| US12233056B2 (en) * | 2022-04-06 | 2025-02-25 | Syntara Limited | Lysyl oxidase inhibitors for treating myeloid malignancies |
| JP2025528475A (ja) * | 2022-08-29 | 2025-08-28 | シンタラ・リミテッド | リシルオキシダーゼの新規選択的阻害剤 |
| MA71743A (fr) * | 2022-11-07 | 2025-05-30 | Eisai R&D Management Co., Ltd. | Procédé de production d'un composé macrolide |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE28819E (en) | 1972-12-08 | 1976-05-18 | Syntex (U.S.A.) Inc. | Dialkylated glycol compositions and medicament preparations containing same |
| US4358603A (en) | 1981-04-16 | 1982-11-09 | Syntex (U.S.A.) Inc. | Acetal stabilized prostaglandin compositions |
| US4454158A (en) | 1981-06-01 | 1984-06-12 | Merrell Toraude Et Compagnie | Allyl amine MAO inhibitors |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4699928A (en) | 1984-07-13 | 1987-10-13 | Merrell Dow Pharmaceuticals Inc. | Fluoroallylamine derivatives |
| US4965288A (en) | 1988-02-25 | 1990-10-23 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
| US5182297A (en) | 1988-02-25 | 1993-01-26 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
| US4943593A (en) | 1988-02-25 | 1990-07-24 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
| US5252608A (en) | 1988-02-25 | 1993-10-12 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
| US5021456A (en) | 1988-02-25 | 1991-06-04 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
| US5059714A (en) | 1988-02-25 | 1991-10-22 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
| DE10216144A1 (de) | 2002-04-12 | 2003-11-06 | Bayer Ag | Substituierte 2-Phenyl-3(2H)-Pyridazinone |
| DE102004056226A1 (de) | 2004-11-22 | 2006-05-24 | Burchardt, Elmar Reinhold, Dr.Dr. | Neuartige Inhibitoren der Lysyloxidase |
| US20080293969A1 (en) | 2005-11-22 | 2008-11-27 | Ge Healthcare Limited | 18F-Labeled Daa Analogues and Method of Labeling These Analogues as Positron Emission Tomography (Pet) Tracers For Imaging Peripheral Benzodiazepine Receptors |
| WO2007120528A2 (en) | 2006-03-31 | 2007-10-25 | La Jolla Pharmaceutical Company | Inhibitors of semicarbazide-sensitive amine oxidase (ssao) and vap-1 mediated adhesion useful for treatment and prevention of diseases |
| US20080293936A1 (en) | 2007-05-23 | 2008-11-27 | Elmar Reinhold Burchardt | Novel inhibitors of lysyl oxidase |
| CA2693310C (en) | 2007-08-02 | 2018-11-27 | Arresto Biosciences, Inc. | Lox and loxl2 inhibitors, antibodies and uses thereof |
| JP2011504485A (ja) | 2007-11-21 | 2011-02-10 | ファーマクシス リミテッド | Ｓｓａｏ／ｖａｐ−１のハロアリルアミン阻害剤およびその用途 |
| WO2011022670A1 (en) | 2009-08-21 | 2011-02-24 | Arresto Biosciences, Inc | In vivo screening assays |
| EP3438087A1 (en) * | 2012-05-02 | 2019-02-06 | Boehringer Ingelheim International GmbH | Substituted 3-haloallylamine inhibitors of ssao and uses thereof |
| WO2016144702A1 (en) | 2015-03-06 | 2016-09-15 | Pharmakea, Inc. | Lysyl oxidase-like 2 inhibitors and uses thereof |
| JP6697809B2 (ja) | 2015-03-06 | 2020-05-27 | ファーマケア，インク． | フッ素化リシルオキシダーゼ様２阻害剤とその使用 |
| EP3317258A4 (en) | 2015-07-01 | 2019-06-26 | Pharmakea, Inc. | LYSYL OXIDASE LIKE 2 INHIBITORS AND USES THEREOF |
| US20180215727A1 (en) | 2015-07-23 | 2018-08-02 | Pharmakea, Inc. | Lysyl oxidase-like 2 inhibitors and uses thereof |
| JP6849197B2 (ja) | 2016-02-12 | 2021-03-24 | ファーマクシス リミテッド | リジルオキシダーゼのインドールおよびアザインドールハロアリルアミン誘導体阻害剤およびその使用 |
| GB201602934D0 (en) | 2016-02-19 | 2016-04-06 | Cancer Res Inst Royal | Compounds |
| WO2018048930A1 (en) | 2016-09-07 | 2018-03-15 | Pharmakea, Inc. | Lysyl oxidase-like 2 inhibitors and uses thereof |
| US20200069648A1 (en) * | 2017-03-02 | 2020-03-05 | Pharmaxis Ltd. | Haloallylamine pyrazole derivative inhibitors of lysyl oxidases and uses thereof |
| GB201716871D0 (en) | 2017-10-13 | 2017-11-29 | Inst Of Cancer Research: Royal Cancer Hospital | Compounds |
-
2019
- 2019-08-02 CN CN201980051571.9A patent/CN112533897B/zh active Active
- 2019-08-02 JP JP2021505981A patent/JP7414803B2/ja active Active
- 2019-08-02 ES ES19844663T patent/ES3010655T3/es active Active
- 2019-08-02 CA CA3105599A patent/CA3105599A1/en active Pending
- 2019-08-02 WO PCT/AU2019/050811 patent/WO2020024017A1/en not_active Ceased
- 2019-08-02 TW TW108127609A patent/TW202019877A/zh unknown
- 2019-08-02 AU AU2019315330A patent/AU2019315330B2/en active Active
- 2019-08-02 AR ARP190102210A patent/AR115906A1/es unknown
- 2019-08-02 EP EP19844663.5A patent/EP3829520B1/en active Active
- 2019-08-02 US US17/265,402 patent/US12178791B2/en active Active
- 2019-08-02 KR KR1020217003279A patent/KR102780601B1/ko active Active
- 2019-08-02 MX MX2021001347A patent/MX2021001347A/es unknown
-
2021
- 2021-01-08 ZA ZA2021/00148A patent/ZA202100148B/en unknown
-
2024
- 2024-11-21 US US18/955,223 patent/US20250082593A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021535087A5 (https=) | ||
| JP7485810B2 (ja) | 癌を処置する方法 | |
| ES2927777T3 (es) | Compuestos y composiciones para el tratamiento de afecciones asociadas a la actividad de NLRP | |
| ES2532357T3 (es) | Derivados de sulfonamida como inhibidores de Nav1.7 para el tratamiento del dolor | |
| DK2609091T3 (en) | Pharmaceutically active compounds as AXL inhibitors | |
| ES2872553T3 (es) | Inhibidores de lisil oxidasa tipo-2 y usos de los mismos | |
| RU2560153C2 (ru) | Триазолпиридиновые соединения, ингибирующие jak, и способы | |
| ES2762193T3 (es) | Agonistas de proteína tirosina fosfatasa 1 que contiene dominio de homología Src-2 y métodos de tratamiento usando la misma | |
| JP2019504898A5 (https=) | ||
| JP2019504899A5 (https=) | ||
| CN101084207A (zh) | 杂环衍生物及其作为硬脂酰CoA去饱和酶抑制剂的用途 | |
| CN102131390A (zh) | 三唑并吡啶jak抑制剂化合物和方法 | |
| JP2013530179A (ja) | 呼吸器合胞体ウイルス（ｒｓｖ）感染の処置に使用するためのウレイド−ピラゾール誘導体 | |
| JP2015506347A5 (https=) | ||
| ES2243469T3 (es) | Compuestos de eter difenilico utiles en terapia. | |
| JPWO2012144463A1 (ja) | 腫瘍治療剤 | |
| JP2025500176A (ja) | カルボン酸バイオアイソスタを含むｄｈｏｄｈ阻害剤 | |
| JPWO2020024017A5 (https=) | ||
| JP2025131661A (ja) | ２－（５－（４－（２－モルホリノエトキシ）フェニル）ピリジン－２－イル）－ｎ－ベンジルアセトアミドの固体形態 | |
| JP2025509830A (ja) | 血液脳関門を通過するｍｌｌ１－ｗｄｒ５タンパク質間相互作用阻害剤化合物及びそれらの使用 | |
| WO2005085201A1 (ja) | 置換又は無置換アミノ基を導入した４－ピリジルアルキルチオ基を有する新規環式化合物 | |
| JP4998258B2 (ja) | 過敏性腸症候群の治療薬 | |
| JP5108934B2 (ja) | ７−（３’、４’−ジアルコキシフェニル）−［１，２，４］トリアゾロ［１，５−ａ］ピリミジン化合物、その製造方法及びこれを含む喘息及び慢性閉鎖性肺疾患を始めとした炎症関連疾患、関節炎、アトピー皮膚炎、癌及び脳疾患の治療及び予防のための薬剤学的組成物 | |
| RU2020142924A (ru) | Производное галоаллиламинсульфона в качестве ингибиторов лизилоксидазы и их применение | |
| HRP20240130T1 (hr) | Derivati izokromena kao inhibitori fosfoinozitid 3-kinaza |